Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III placebo-controlled study of K-237 in mild COVID-19
jRCT2031210316Phase 3Completed
- Sponsor
- Kowa Company, Ltd.
- Start
- Oct 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing K-237 group with Placebo group (2 arms). Started Oct 2021; status: completed.
02
Drugs
ursodeoxycholic acid
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCT2031210316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210316.